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Monoclonal antibodies directed toward the complementarity determining region (CDR)3-like loop of the aminoterminal
domain of CD4 have been shown to inhibit the replication of human immunodeficiency virus (HIV) in CD4 positive T cells. The
mechanism of action of these antibodies is not yet elucidated, although several observations suggest that they inhibit viral
transcription by signal transduction through the CD4 molecule, potentially implicating the activation of a protein tyrosine
kinase (PTK) cascade. Since CD45 is the major protein tyrosine phosphatase associated to the plasma membrane in T cells,
and has been shown to regulate the activity of several PTK, we postulated that CD45 may be necessary for the inhibitory
action of the CDR3-like specific anti-CD4 antibodies. Therefore we tested the effect of one such anti-CD4 monoclonal
antibody, 13B8.2, in repressing HIV replication in CD45 positive cell lines and CD45 deficient variants. Our data show that
cells respond to 13B8.2 postinfection treatment regardless of CD45 expression, indicating that neither CD45 nor PTK
regulated by CD45 are implicated in the mechanism of action of this antibody. © 1998 Academic Press
CD4 positive T lymphocytes can be infected by human
immunodeficiency virus (HIV), the agent responsible for
acquired immunodeficiency syndrome. However, the ex-
pression of viral genes appears to require the host cell to
be activated (1, 2), resulting in the induction of cellular
transcription factors able to stimulate the viral promoter,
such as NFkB, AP-1, and NF-AT. Numerous studies indi-
cate that HIV binding to its primary cellular receptor,
CD4, can activate a signal transduction cascade in T
cells (3–10). The earliest step of the signaling cascade
appears to involve a src family protein tyrosine kinase
(PTK) associated with the cytoplasmic domain of CD4,
p56lck (3, 7, 11). The activity of this kinase is primarily
controlled, both positively and negatively, by the level of
phosphorylation of several tyrosine residues (12–15).
CD45, one of the major glycoproteins expressed on
the surface of T lymphocytes, is required for the early
steps of T cell responses to stimulation via the T cell
receptor (16–18). These responses involve activation of a
series of PTK, including p56lck. The cytoplasmic portion
of CD45 possesses constitutive protein tyrosine phos-
phatase activity and indeed includes two domains anal-
ogous to soluble protein tyrosine phosphatases. Al-
though physiological substrates of CD45 are not known,
several src family kinases, including p56lck, have been
proposed as potential candidates. Indeed CD45 is able
to dephosphorylate in vitro the two main regulatory phos-
phorylation sites of p56lck, Y-394, and Y-505 (19, 20). This
in vitro observation appears to be relevant since both
residues are hyperphosphorylated in CD45-deficient cell
lines, where the kinase is hyperactive (19). In addition,
CD45 can affect the rate of HIV replication by modulating
NFkB activation (21).
Our previous work has shown that some anti-CD4
antibodies are able to block HIV infection at a postentry
step in cultures of CD4 positive cells (22, 23). The extra-
cellular region of the CD4 molecule contains four immu-
noglobulin-like domains (D1–D4). The viral envelope gly-
coprotein gp120 recognizes a particular region of D1, the
complementarity determining region (CDR) 2-like loop.
Monoclonal antibodies specific for another sequence of
D1, the CDR3-like region, were shown not to prevent
binding and fusion of HIV to CD4 positive cells, but rather
to inhibit a later step of the infectious cycle (22, 24).
Further studies suggested that these antibodies could
prevent early viral transcription through inhibition of
NFkB translocation (25). Signal transduction through the
CD4 cytoplasmic tail appeared to be involved in the
mechanism of action of 13B8.2 mAb (26), suggesting a
putative role for p56lck and possibly other PTK in this
process. We reasoned that CD45, as a modulator of PTK
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activity, could be implicated in the action of the anti-
CDR3-like monoclonal antibodies. Therefore, we investi-
gated the effect of such an antibody, 13B8.2, on HIV
replication in CD45 positive and CD45 deficient T cell
lines.
To this end, we used two previously described (16, 27,
28) Jurkat sublines, JE6.1 and JDW, and their respective
CD45- variants, J45.01 and JCD45- (clone 25). J45.01 was
originally derived by mutagenesis of JE6.1 and selection
of CD45 negative cells. JCD45- is a natural CD45 null
variant of JDW. Flow cytometry analysis (Fig. 1) indicated
that JE6.1, J45.01, and JDW expressed similar amounts of
CD4 at their surface. JCD45- expressed very low, but
detectable levels of CD4. CD45 levels of expression
were high in the parental sublines, low in J45.01 subline,
and almost undetectable in JCD45- cells, as previously
described (16, 27). The amount of CD45 at the cell sur-
face correlated with the CD45 tyrosine phosphatase ac-
tivity present in the various sublines (Fig. 2), as mea-
sured by an in vitro assay following immunoprecipitation
of CD45 as previously described (29). In this assay, both
variant sublines had undetectable activity in contrast to
high activity in parental Jurkat lines.
To assess the role of CD45 in the antiviral effect of a
monoclonal antibody directed toward the CDR3-like re-
gion of CD4, 13B8.2, CD45 positive, and CD45 deficient
cells were infected with 100 3 TCID50 (50% tissue culture
FIG. 1. Expression of CD4 and CD45 on two parental CD45 positive Jurkat strains, JE6.1 and JDW, and their respective CD45 deficient variants, J45.01
and JCD45-. Flow cytometry analysis of the cells after staining with FITC-coupled goat anti-mouse Ab alone (negative control, dashed line), BL4
anti-CD4 mAb (Immunotech SA, Marseille, France) and FITC-coupled goat anti-mouse Ab (CD4 staining, thick line), or 9.4 anti-CD45 mAb (American
Type Culture Collection, Bethesda, MD) and FITC-coupled goat anti-mouse Ab (CD45 staining, thin line).
FIG. 2. CD45 phosphatase activity in two parental CD45 positive
Jurkat strains, JE6.1 and JDW, and their respective CD45 deficient
variants, J45.01 and JCD45-. CD45 was immunoprecipitated from cel-
lular lysates using 9.4 mAb, and phosphatase activity was measured in
vitro as described (29). Results represent average 6 standard deviation
of quadruplicates.
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infective dose) of HIV-1 for 30 min at 4°C, washed, and
cultivated at a cell density of 105 cells/ml in medium with
or without 13B8.2 mAb. On days 3, 7, 10, 14, and 17
postinfection, viral production was measured by assay-
ing the reverse transcriptase activity present in the cul-
ture supernatant as described (30). All four sublines
could be readily infected by HIV-1, although viral produc-
tion was slower and weaker in JCD45-, probably because
of a lower CD4 expression. When cells were continu-
ously treated with the anti-CDR3-like mAb 13B8.2 postin-
fection, viral production was suppressed, at least for
several days, in all sublines (Fig. 3B). In the course of
these experiments, cell proliferation was not significantly
affected by 13B8.2 treatment. Only in conditions of pro-
ductive viral infection were slightly lower numbers of
cells obtained due to virus cytopathogenicity (Fig. 3A).
However, inhibition of viral replication was more pro-
longed in JDW and JCD45- than in JE6.1 and J45.01 cells.
Thus there is no correlation between CD45 expression
and responsiveness to 13B8.2 treatment, demonstrating
that CD45 is not required for the inhibitory action of this
antibody. One could argue that another protein tyrosine
phosphatase could replace CD45 in the CD45 deficient
sublines. However, this appears unlikely since most
CD45 deficient cell lines, including J45.01, are defective
for responses to stimulation through the T cell receptor
(16–18). One exception is constituted by the JCD45- cell
line, which has been shown to respond to TCR stimula-
tion because of increased expression of another PTK,
p72syk, that can intervene in TCR-mediated processes
(31). This protein is also present in the parental cell line,
JDW. Whether the more durable inhibition of viral repli-
cation by 13B8.2 treatment observed in JDW and JCD45-
as compared to JE6.1 and J45.01 sublines is related to
increased expression of p72syk is not known.
Earlier results of the laboratory showed that the cyto-
plasmic tail of CD4 was necessary for the responsive-
ness of the cells to 13B8.2 treatment (26). These data
strongly suggested that signal transduction was involved
in the mechanism of action of 13B8.2 mAb. This could be
FIG. 3. 13B8.2 postinfection treatment inhibits viral replication in HIV-1 infected CD45 positive and CD45 deficient cells. Cells were infected with
100 3 TCID50 of HIV-1 Lai for 30 min at 4°C, washed five times at 4°C, and grown at a cell density of 10
5 cells/ml in complete medium with (E) or
without ({) 20 mg/ml 13B8.2 mAb. Noninfected cells are shown in control (h). On days 3, 7, 10, 14, and 17 postinfection, trypan blue excluding cells
were counted (A) and adjusted to 105 cells/ml in fresh medium. Viral replication was measured by assay of the reverse transcriptase activity (RT)
present in culture supernatants as previously described (30) (B). Results represent mean values from five experiments (JE6.1 and J45.01) or two
experiments (JDW and JCD45-).
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achieved either by the inhibition of cellular activation
following HIV–CD4 interaction or by induction of an in-
dependent negative signaling cascade, either mecha-
nism resulting in the inhibition of NFkB nuclear translo-
cation and, as a consequence, in the repression of HIV
genome transcription, as shown in previous reports (22,
24–26). Our present data show that there is no apparent
difference in 13B8.2 responsiveness in CD45 deficient
versus CD45 positive cells. However, the phosphoryla-
tion state and basal activity of p56lck in CD45 deficient
cells have been described to be constitutively elevated
compared to CD45 positive cells (19). Together, this
would suggest that 13B8.2 may not act via p56lck or other
PTK affected by CD45. The conclusion that p56lck is not
involved is supported by the observations that 13B8.2
mAb also inhibits HIV-1 replication in MT2 (25) and U937
(26) cell types, two CD4 positive cell lines lacking p56lck
expression.
All as yet known signals initiated through CD4 are
mediated through the activation of p56lck. It is possible
that other signal transducing molecules that interact
with CD4 exist. Alternatively, one has to consider the
possibility that HIV related activation may involve sig-
nalization through the virus coreceptors. Indeed, a
family of receptors to chemokines have been recently
described as coreceptors for HIV (32). These recep-
tors consist of seven transmembrane domain proteins,
which are likely to associate with trimeric GTP-binding
proteins. One could imagine that HIV binding to CD4
and a coreceptor would induce the interaction of the
CD4 cytoplasmic tail with intracellular domains of the
coreceptor, allowing synergistic signals to emerge.
Whether the 13B8.2 mAb affects signaling through
these molecules or other unidentified partners awaits
further investigation.
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